AIM: To evaluate safety and feasibility of autologous bone marrow-enriched CD34+ hematopoietic stem cell Tx through the hepatic artery in patients with decompensated cirrhosis. METHODS: Four patients with decompensated cirrhosis were included. Approximately 200 mL of the bone marrow of the patients was aspirated, and CD34+ stem cells were selected. Between 3 to 10 million CD34+ cells were isolated. The cells were slowly infused through the hepatic artery of the patients. RESULTS: Patient 1 showed marginal improvement in serum albumin and no significant changes in other test results. In patient 2 prothrombin time was decreased; however, her total bilirubin, serum creatinine, and Model of End-Stage Liver Disease (MELD) score worsened at the end of follow up. In patient 3 there was improvement in serum albumin, porthrombin time (PT), and MELD score. Patient 4 developed radiocontrast nephropathy after the procedure, and progressed to type 1 hepatorenal syndrome and died of liver failure a few days later. Because of the major side effects seen in the last patient, the trial was prematurely stopped. CONCLUSION: Infusion of CD34+ stem cells through the hepatic artery is not safe in decompensated cirrhosis. Radiocontrast nephropathy and hepatorenal syndrome could be major side effects. However, this study does not preclude infusion of CD34+ stem cells through other routes.
AIM: To evaluate safety and feasibility of autologous bone marrow-enriched CD34+ hematopoietic stem cell Tx through the hepatic artery in patients with decompensated cirrhosis. METHODS: Four patients with decompensated cirrhosis were included. Approximately 200 mL of the bone marrow of the patients was aspirated, and CD34+ stem cells were selected. Between 3 to 10 million CD34+ cells were isolated. The cells were slowly infused through the hepatic artery of the patients. RESULTS:Patient 1 showed marginal improvement in serum albumin and no significant changes in other test results. In patient 2 prothrombin time was decreased; however, her total bilirubin, serum creatinine, and Model of End-Stage Liver Disease (MELD) score worsened at the end of follow up. In patient 3 there was improvement in serum albumin, porthrombin time (PT), and MELD score. Patient 4 developed radiocontrast nephropathy after the procedure, and progressed to type 1 hepatorenal syndrome and died of liver failure a few days later. Because of the major side effects seen in the last patient, the trial was prematurely stopped. CONCLUSION: Infusion of CD34+ stem cells through the hepatic artery is not safe in decompensated cirrhosis. Radiocontrast nephropathy and hepatorenal syndrome could be major side effects. However, this study does not preclude infusion of CD34+ stem cells through other routes.
Authors: Yoon-Young Jang; Michael I Collector; Stephen B Baylin; Anna Mae Diehl; Saul J Sharkis Journal: Nat Cell Biol Date: 2004-05-09 Impact factor: 28.824
Authors: Terry C Burns; Xilma R Ortiz-González; María Gutiérrez-Pérez; C Dirk Keene; Rohit Sharda; Zachary L Demorest; Yuehua Jiang; Molly Nelson-Holte; Mario Soriano; Yasushi Nakagawa; María Rosario Luquin; Jose Manuel Garcia-Verdugo; Felipe Prósper; Walter C Low; Catherine M Verfaillie Journal: Stem Cells Date: 2005-12-22 Impact factor: 6.277
Authors: A Gasbarrini; G L Rapaccini; S Rutella; M A Zocco; P Tittoto; G Leone; P Pola; G Gasbarrini; C Di Campli Journal: Dig Liver Dis Date: 2006-07-27 Impact factor: 4.088
Authors: S A Malek-Hosseini; A R Mehdizadeh; H Salahi; M Saberi-Firouzi; K Bagheri-Lankarani; A Bahador; M H Imanieh; S Nik-Eghbalian; M Lahsaee; M B Khosravi; M M Arasteh; M H Bagheri; B Geramizadeh; A Razmkon; S Z Tabei Journal: Transplant Proc Date: 2005-09 Impact factor: 1.066
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Myrtle Y Gordon; Natasa Levicar; Madhava Pai; Philippe Bachellier; Ioannis Dimarakis; Faisal Al-Allaf; Hanane M'Hamdi; Tamara Thalji; Jonathan P Welsh; Stephen B Marley; John Davies; Francesco Dazzi; Federica Marelli-Berg; Paul Tait; Raymond Playford; Long Jiao; Steen Jensen; Joanna P Nicholls; Ahmet Ayav; Mahrokh Nohandani; Farzin Farzaneh; Joop Gaken; Rikke Dodge; Malcolm Alison; Jane F Apperley; Robert Lechler; Nagy A Habib Journal: Stem Cells Date: 2006-03-23 Impact factor: 6.277
Authors: Christopher Booth; Tom Soker; Pedro Baptista; Christina L Ross; Shay Soker; Umar Farooq; Robert J Stratta; Giuseppe Orlando Journal: World J Gastroenterol Date: 2012-12-21 Impact factor: 5.742